Group 1 - The company announced the successful completion of the first subject enrollment and administration in the Phase II clinical trial of "GB08 Injection," developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd [1][2] - "GB08 Injection" is the company's first independently developed Class I innovative drug, designed to address the needs of clinical patients with growth hormone deficiency in children, utilizing DNA recombinant technology to enhance safety and patient compliance [1][2] - The clinical trial aims to evaluate the efficacy and safety of "GB08 Injection" in treating children with growth hormone deficiency, with ethical approval obtained from Zhejiang University School of Medicine Affiliated Children's Hospital [2] Group 2 - The successful enrollment of the first subject in the Phase II clinical trial of "GB08 Injection" is not expected to have a significant impact on the company's recent financial status or operating performance [3]
科兴生物制药股份有限公司 自愿披露关于GB08注射液II期临床试验完成首例受试者入组的公告